

## Financial Conflict of Interest for Public Health Service (PHS) Funded Research

Key Points:

(1).	Personnel involved with research funded under Public Health Service grants or cooperative agreements will be free from bias resulting from financial conflicts of interest.
(2).	A Principal Investigator (PI) that applies for PHS funded research must complete the Clinical Research Potential Conflict of Interest Disclosure Form and submit to the Designated Official at the same time as submitting the PHS funding application.
(3).	If a PI receives PHS research funding, they must be trained by FMCNA Corporate Compliance on the applicable policies & procedures.
(4).	FMCNA will determine if a Financial Conflict of Interest (FCOI) exists and if it does exist, take steps to manage the FCOI.
(5).	FMCNA will maintain and enforce PHS Funded Conflict of Interest policies & procedures and post them on the publicly accessible company web site.
(6).	Upon request from the public, FMCNA will provide a written report (within 5 business days) with information concerning an investigator's FCOI.

DOCUMENT NUMBER	DOCUMENT REVISION #	DOCUMENT REVISION DATE	EFFECTIVE DATE
COR-CR-G-000-001A	11/27/2013		
Title: Financial Conflict of Interest f Research	Page 1 of 14		
©2013, Fresenius Medical Care Holdings, Inc. All Rights Reserved.			



Applies To	The following when seeking or participating in PHS funded research:					
	<ul><li>Each FMCNA, or FMCNA affiliated:</li><li>entity, that is applying for, or that receives, PHS research funding by means of a grant or cooperative agreement,</li></ul>					
	• investigator w research and		cipate in, or are partici	pating in such		
		o is responsible for the ies, and responsible pr	contracting and managospective contractors.	gement of		
Purpose	research funded un	To ensure that personnel involved with the design, conduct, and reporting of research funded under PHS grants, cooperative agreements or contracts will be free from bias resulting from financial conflicts of interest.				
What is a Financial Conflict of Interest (FCOI)?	A significant financial interest that could directly and significantly affect the design, conduct, or reporting of PHS-funded research.					
Definitions	<i>Conflict of Interest Committee (COIC)</i> – committee comprised of representatives from Legal, Compliance and the Medical Office that determines and manages financial conflicts of interest for PHS-funded research.					
	Designated Official - the FMCNA Clinical Research Compliance Officer.					
	<i>Entity</i> – company or corporation.					
	<i>Financial Conflict of Interest</i> – significant financial interest that could directly and significantly affect the design, conduct, or reporting of PHS-funded research.					
DOCUME	DOCUMENT NUMBER         DOCUMENT REVISION #         DOCUMENT REVISION DATE         EFFECTIVE DATE					

COR-CR-G-000-001A			11/27/2013	
Title: Financial Conflict of Interest t Research	Page 2 of 14			
©2013, Fresenius Me	©2013, Fresenius Medical Care Holdings, Inc. All Rights Reserved.			



*Financial Interest* – anything of monetary value, whether or not the value is readily ascertainable.

*FMCNA Institutional Responsibilities* - the Investigator's professional responsibilities that the investigator performs for or on behalf of FMCNA. Such activities may include research, research consultation, teaching, professional practice and medical directorship, FMCNA committee memberships, Medical Advisory Boards and service on panels such as IRBs or data safety monitoring boards.

*Investigator* –the project director, principal investigator, co-investigator, and any other person, regardless of title or position, who is responsible for the design, conduct or reporting of PHS funded research (or applications of the same), which may include collaborators or consultants.

*Key Personnel* – includes the PD/PI and any other personnel considered to be essential to work performance, and identified as key personnel in the contract proposal and contract.

*Manage* – address financial conflict of interest, which can include reducing or eliminating the financial conflict of interest to ensure, to the extent possible, that the design, conduct, and reporting of research will be free from bias.

**PHS** or the U.S. Public Health Service - the unit within the Department of Health and Human Services that includes the Office of Public Health and Science and the following Operating Divisions: Agency for Healthcare Research and Quality, Agency for Toxic Substances and Disease Registry, Centers for Disease Control and Prevention, Food and Drug Administration, Health Resources and Services Administration, Indian Health Service, National Institutes of Health, and the Substance Abuse and Mental Health Services Administration, and the offices of the Regional Health Administrators.

*PHS funded research* –research, financially supported by PHS (e.g., NIH, CDC, etc.) through grants, contracts, or cooperative agreements, and also

DOCUMENT NUMBER	DOCUMENT REVISION #	DOCUMENT REVISION DATE	EFFECTIVE DATE
COR-CR-G-000-001A			11/27/2013
Title: Financial Conflict of Interest for Public Health Service (PHS) Funded       Page         Research       Page			
©2013, Fresenius Medical Care Holdings, Inc. All Rights Reserved.			



includes applications for any of the same. Such research funding may be provided, for example, as a research grant, career development award, center grant, individual fellowship award, infrastructure award, FMCNA training grant, program project, or research resources award.

*PHS Awarding Component* – the organizational unit of the PHS that funds the research that is subject to the regulation.

*Research* - a systematic investigation, study or experiment designed to develop or contribute to generalizable knowledge relating broadly to public health, including behavioral and social-sciences research. The term encompasses basic and applied research (e.g., a published article, book or book chapter) and product development (e.g., a diagnostic test, medical device or drug).

*Proprietary Interest* - in the tested product includes, but is not limited to, a patent, trademark, copyright or licensing agreement.

**PD/PI** – a project director or principal Investigator of a PHS-funded research project; the PD/PI is included in the definitions of senior/key personnel and Investigator.

Significant Financial Interest (SFI) SFI is anything of monetary value of the Investigator (or those of the Investigator's spouse and dependent children) that appears to be related to the Investigator's FMCNA Institutional Responsibilities. This includes:

- Intellectual property rights and interests (e.g. patents, copyrights)
- Reimbursed or sponsored travel (i.e. paid on behalf of the Investigator and not reimbursed to the Investigator so the exact monetary value may not be known).

SFI does not include:

• Travel reimbursed or sponsored by a Federal state, or local government agency, Institution of higher education, an academic teaching hospital, or a research institute affiliated with an Institution

DOCUMENT NUMBER	DOCUMENT REVISION #	DOCUMENT REVISION DATE	EFFECTIVE DATE	
COR-CR-G-000-001A	11/27/2013			
Title: Financial Conflict of Interest for Public Health Service (PHS) Funded       Page 4 of 14         Research       Page 4 of 14				
©2013, Fresenius Medical Care Holdings, Inc. All Rights Reserved.				



of higher education.

• Salary, royalties, or other remuneration paid by FMCNA to the Investigator if the Investigator is currently employed or otherwise appointed by FMCNA.

A Significant Financial Interest exists	If the value of remuneration received from the entity		
For a <b>publicly</b> traded entity	in the past twelve months and value of any equity interest when aggregated exceeds \$5,000		
For a <b>non-publicly</b> traded entity			
	Investigator (or the Investigator's spouse or dependent children) holds any equity interest (i.e. stock, stock option, or other ownership interest) in entity		

SignificantA SFFinancialInterest vs.FinancialA FinConflict ofConflInterestcould

A SFI is not always a FCOI.

A Financial Conflict of Interest (FCOI) exists when the applicable FMCNA Conflict of Interest Committee (COIC) reasonably determines that an SFI could directly and significantly affect the design, conduct, or reporting of the research project.

FMCNA will collect Investigator's financial arrangements with:

- FMCNA and affiliates
- Entities outside of FMCNA that could be reasonably related to FMCNA Institutional responsibilities
- Entities that could potentially be affected by the results of the research project

FMCNA will determine if the financial arrangements pose a financial conflict of interest.

DOCUMENT NUMBER	DOCUMENT REVISION #	DOCUMENT REVISION DATE	EFFECTIVE DATE
COR-CR-G-000-001A			11/27/2013
Title: Financial Conflict of Interest f Research	Page 5 of 14		
©2013, Fresenius Me	d.		



Responsibilities of Institutions	FMCNA will:				
Regarding FCOI	• Maintain an	• Maintain an up-to-date, written, enforced policy on FCOI.			
		OI policy to a publicly a n full compliance with			
		ritten and administrativ reduce or eliminate co		re to identify	
	of interest, tl significant fi require each	Investigator of the Inst ne Investigator's respon- nancial interests, and of Investigator to comple in research related to an ears.	nsibilities regarding dia of the applicable regula te training regarding th	sclosure of ations, and he same prior	
	to evaluate the treatment ha with a finance the Institution financial cor	rmines that a PHS-fund the safety or effectivene s been designed, condu- cial conflict of interest on, then FMCNA requir- inflict of interest in each and to request an adder s.	ess of a drug, medical of acted or reported by an that was not managed res the Investigator to of a public presentation of	device, or Investigator or reported by disclose the f the results of	
	business day Senior/Key j o Inv o Inv o Nai held o Nat	ac accessibility to FCO rs to a request concerning personnel. The response estigator's name estigator's title and role me of the entity in whice d ure of the significant fit proximate dollar value • Dollar ranges are p • \$0-\$4,999	ng an Investigator, PD se shall include: e with respect to the re ch the significant finan inancial interest of the significant finar	/PI and esearch project cial interest is	
DOCUME	NT NUMBER	DOCUMENT REVISION #	DOCUMENT REVISION DATE	EFFECTIVE DATE	
COR-CR-G-00	00-001A			11/27/2013	
Title: Financial Research	Conflict of Interest f	For Public Health Service	(PHS) Funded	Page 6 of 14	
©2	2013, Fresenius Me	edical Care Holdings, I	nc. All Rights Reserve	d.	



•	\$5,000-\$9,999
---	-----------------

- \$10,000-\$19,999
- \$20,000-\$100,000 in increments of \$20,000
- >\$100,000 in increments of \$50,000
- Or a statement that the interest cannot be readily determined through reference to public prices or other measures of fair market value.
- Statement that information is current as of the date on the letter is subject to be updated by the investigator at least annually or within 60 days of identifying a new financial conflict of interest.
- It is up to any requestor to ask for updated information.

Investigator Responsibilities	Each investigator must:			
	1	Submit an FMCNA financial disclosure statement to the FMCNA Designated Official • Complete the Clinical Research Potential Conflict of Interest Disclosure Form <u>Note:</u> all investigators listed on the grant must complete the disclosure form before the grant may be submitted.	<ul> <li>No later than at the time of application for PHS-funded research</li> <li>At least annually, by the anniversary date during the period of the award</li> <li>Report any new Significant Financial Interests, or any changes to a previously disclosed interest, to FMCNA within 30 days of discovering or acquiring a new SFI</li> </ul>	
	2	Complete training prior to engaging in PHS-funded research:	<ul> <li>At least every 4 years, and within a reasonable time period if:</li> <li>FMCNA Financial Conflict of Interest policies change in a manner that affects Investigator</li> </ul>	

DOCUMENT NUMBER	DOCUMENT REVISION #	DOCUMENT REVISION DATE	EFFECTIVE DATE
COR-CR-G-000-001A	11/27/2013		
Title: Financial Conflict of Interest f Research	Page 7 of 14		
©2013, Fresenius Me	d.		



	requirements.				
	• An Investigator is new to a FMCNA entity.				
	• FMCNA finds that an Investigator is not in compliance with FMCNA's Financial Conflict of Interest policy or management plan.				
	• If FMCNA performs PHS-funded research as a sub recipient.				
Conflict of Interest Committee	<ul> <li>FMCNA will establish a Conflicts of Interest Committee (COIC) for</li> <li>Fresenius Medical Services and a second COIC for the Renal Therapies</li> <li>Group/Renal Research Institute. They will include representation from: <ul> <li>Legal</li> <li>Compliance</li> <li>Medical Office</li> </ul> </li> <li>The Medical Office representation must be different for the two committees.</li> </ul>				
FMCNA Entity Applying /	Financial conflict of interest responsibilities:				
Conducting PHS Research	Each FMCNA entity applying for and conducting PHS funded research will:				
	Solicit and review disclosure statements (FMCNA Clinical Research				
	Potential Conflict of Interest Disclosure Form) from each Investigator				
	planning to participate in federally-funded research.				
FMCNA Designated Official Responsibilities	The Designated Official is responsible for the following:				

DOCUMENT NUMBER	DOCUMENT REVISION #	DOCUMENT REVISION DATE	EFFECTIVE DATE		
COR-CR-G-000-001A			11/27/2013		
Title: Financial Conflict of Interest f Research	Page 8 of 14				
©2013, Fresenius Medical Care Holdings, Inc. All Rights Reserved.					



Report regularly to the Conflict of Interest Committee, including failure of an Investigator to comply with this policy or management plan. Review disclosures prior to the expenditure of funds after receipt of disclosures of significant financial interests and determine whether there appears to be any financial conflict of interest. Review disclosures for new investigators within 60 days after receipt of disclosures of significant financial interests and determine whether there appears to be any financial conflict of interest. Review disclosures for investigators that were received after the research project within 60 days after receipt of disclosures of significant financial interests and determine whether there appears to be any financial conflic of interest. Report failure of an Investigator to comply with this policy and or financial conflict management plan to the PHS Awarding Component After reviewing disclosures, if an FCOI appears to exist, present finding to the applicable COIC committee.		Establish guidelines to identify conflicting interests.
Review disclosures prior to the expenditure of funds after receipt of disclosures of significant financial interests and determine whether there appears to be any financial conflict of interest. Review disclosures for new investigators within 60 days after receipt of disclosures of significant financial interests and determine whether there appears to be any financial conflict of interest. Review disclosures for investigators that were received after the research project within 60 days after receipt of disclosures of significant financial interests and determine whether there appears to be any financial conflict of disclosures of significant financial interests and determine whether there appears to be any financial conflict of interest. Report failure of an Investigator to comply with this policy and or financial conflict management plan to the PHS Awarding Component After reviewing disclosures, if an FCOI appears to exist, present finding to the applicable COIC committee.		Take action to ensure FCOI are reported, managed, reduced or eliminate
Review disclosures prior to the expenditure of funds after receipt of disclosures of significant financial interests and determine whether there appears to be any financial conflict of interest. Review disclosures for new investigators within 60 days after receipt of disclosures of significant financial interests and determine whether there appears to be any financial conflict of interest. Review disclosures for investigators that were received after the research project within 60 days after receipt of disclosures of significant financial interests and determine whether there appears to be any financial conflict of interest. Report failure of an Investigator to comply with this policy and or financial conflict management plan to the PHS Awarding Component After reviewing disclosures, if an FCOI appears to exist, present finding to the applicable COIC committee.		Report regularly to the Conflict of Interest Committee, including failure
<ul> <li>disclosures of significant financial interests and determine whether there appears to be any financial conflict of interest.</li> <li>Review disclosures for new investigators within 60 days after receipt of disclosures of significant financial interests and determine whether there appears to be any financial conflict of interest.</li> <li>Review disclosures for investigators that were received after the research project within 60 days after receipt of disclosures of significant financial interests and determine whether there appears to be any financial conflict of interest.</li> <li>Review disclosures for investigators that were received after the research project within 60 days after receipt of disclosures of significant financial interests and determine whether there appears to be any financial conflict of interest.</li> <li>Report failure of an Investigator to comply with this policy and or financial conflict management plan to the PHS Awarding Component</li> <li>After reviewing disclosures, if an FCOI appears to exist, present finding to the applicable COIC committee.</li> </ul>		of an Investigator to comply with this policy or management plan.
<ul> <li>appears to be any financial conflict of interest.</li> <li>Review disclosures for new investigators within 60 days after receipt of disclosures of significant financial interests and determine whether there appears to be any financial conflict of interest.</li> <li>Review disclosures for investigators that were received after the research project within 60 days after receipt of disclosures of significant financial interests and determine whether there appears to be any financial conflict of interest.</li> <li>Report failure of an Investigator to comply with this policy and or financial conflict management plan to the PHS Awarding Component</li> <li>After reviewing disclosures, if an FCOI appears to exist, present finding to the applicable COIC committee.</li> </ul>		Review disclosures prior to the expenditure of funds after receipt of
Review disclosures for new investigators within 60 days after receipt of disclosures of significant financial interests and determine whether there appears to be any financial conflict of interest. Review disclosures for investigators that were received after the research project within 60 days after receipt of disclosures of significant financial interests and determine whether there appears to be any financial conflict of interest. Report failure of an Investigator to comply with this policy and or financial conflict management plan to the PHS Awarding Component After reviewing disclosures, if an FCOI appears to exist, present finding to the applicable COIC committee.		
<ul> <li>disclosures of significant financial interests and determine whether there appears to be any financial conflict of interest.</li> <li>Review disclosures for investigators that were received after the research project within 60 days after receipt of disclosures of significant financial interests and determine whether there appears to be any financial conflict of interest.</li> <li>Report failure of an Investigator to comply with this policy and or financial conflict management plan to the PHS Awarding Component</li> <li>After reviewing disclosures, if an FCOI appears to exist, present finding to the applicable COIC committee.</li> </ul>		appears to be any financial conflict of interest.
<ul> <li>appears to be any financial conflict of interest.</li> <li>Review disclosures for investigators that were received after the research project within 60 days after receipt of disclosures of significant financial interests and determine whether there appears to be any financial conflict of interest.</li> <li>Report failure of an Investigator to comply with this policy and or financial conflict management plan to the PHS Awarding Component</li> <li>After reviewing disclosures, if an FCOI appears to exist, present finding</li> </ul>		Review disclosures for new investigators within 60 days after receipt of
Review disclosures for investigators that were received after the research project within 60 days after receipt of disclosures of significant financial interests and determine whether there appears to be any financial conflic of interest. Report failure of an Investigator to comply with this policy and or financial conflict management plan to the PHS Awarding Component After reviewing disclosures, if an FCOI appears to exist, present finding to the applicable COIC committee.		0
<ul> <li>project within 60 days after receipt of disclosures of significant financial interests and determine whether there appears to be any financial conflict of interest.</li> <li>Report failure of an Investigator to comply with this policy and or financial conflict management plan to the PHS Awarding Component</li> <li>After reviewing disclosures, if an FCOI appears to exist, present finding to the applicable COIC committee.</li> </ul>		appears to be any financial conflict of interest.
<ul> <li>interests and determine whether there appears to be any financial conflict of interest.</li> <li>Report failure of an Investigator to comply with this policy and or financial conflict management plan to the PHS Awarding Component</li> <li>After reviewing disclosures, if an FCOI appears to exist, present finding to the applicable COIC committee.</li> </ul>	_	Review disclosures for investigators that were received after the research
of interest. Report failure of an Investigator to comply with this policy and or financial conflict management plan to the PHS Awarding Component After reviewing disclosures, if an FCOI appears to exist, present finding to the applicable COIC committee. Note: If SFI is not reported or reviewed within a timely manner, perform a		
financial conflict management plan to the PHS Awarding Component After reviewing disclosures, if an FCOI appears to exist, present finding to the applicable COIC committee.		
financial conflict management plan to the PHS Awarding Component After reviewing disclosures, if an FCOI appears to exist, present finding to the applicable COIC committee.		
After reviewing disclosures, if an FCOI appears to exist, present finding to the applicable COIC committee.		
to the applicable COIC committee. Note: If SFI is not reported or reviewed within a timely manner, perform a		financial conflict management plan to the PHS Awarding Component
		• • • • •
etrospective review of the investigator's actions and if applicable, report	1	ote: If SFI is not reported or reviewed within a timely manner, perform a
	e	trospective review of the investigator's actions and if applicable, report

DOCUMENT NUMBER	DOCUMENT REVISION #	DOCUMENT REVISION DATE	EFFECTIVE DATE	
COR-CR-G-000-001A			11/27/2013	
Title: Financial Conflict of Interest f Research	Page 9 of 14			
©2013, Fresenius Medical Care Holdings, Inc. All Rights Reserved.				



iterest?	If	The	<b>n</b>			
	FMCNA		Notify the In	vestigator	r	
	determin		•	0	plan that specifies act	tions that have
	that the S				en to manage the FCC	
	is a FCO		Monitor com		U	-
	FMCNA	· · · · · · · · · · · · · · · · · · ·		-	to the PHS Awarding	Component
	will:			-	dates for the duration	· 1
	Example	s of an F			n may include, but is i	
	-		-		nflicts of interest (i.e.	
			g or publishin		,	
	• <u>I</u>	oisclosur	e of FCOI dir	ectly to h	uman subjects in the	study
	• A	ppointm	ent of an inde	ependent	monitor who can prot	ect the design,
	c	onduct, a	and reporting	of the res	earch against bias	C A
	• N	Iodificat	ion of the res	earch stuc	ły	
	• (	hange of	f personnel or	disqualif	fication of personnel f	from the study
					g the financial conflic	
	The FM	CNA Des	signated Offic	cial will n	nonitor compliance to	the
	managen	nent plan	for the durat	ion of the	study and provide pe	eriodic updates
	to the ap	plicable	COIC.			
					he expenditure of fun	
	not requi	red to su	bmit a FCOI	report to	the PHS Awarding C	omponent.
OI Report to	A Financi	al Confl	ict of Interest	report su	bmitted to the PHS A	warding
				-	bmitted to the PHS A the following:	warding
IS Awarding				-	bmitted to the PHS A the following:	warding
IS Awarding	Compone	nt must o	contain, at a n	-		warding
IS Awarding	Compone	nt must o ect numl	contain, at a n	ninimum,	the following:	warding
IS Awarding	Compone	nt must o ect numl	contain, at a n	-	the following:	warding
IS Awarding	Compone	nt must o ect numl	contain, at a n	ninimum,	the following:	warding
DI Report to IS Awarding omponent	Compone 1 Proj 2 PD/	nt must o ect numl PI or Co	contain, at a n	ninimum, If multip	the following:	
IS Awarding	Compone 1 Proj 2 PD/	nt must o ect numl PI or Co	contain, at a n per ntact PD/PI Investigator	ninimum, If multip Name of	the following: ple used f the Investigator with	the financial
IS Awarding	Compone 1 Proj 2 PD/	nt must of ect numl PI or Com ne of the	contain, at a n oer ntact PD/PI	ninimum, If multip Name of	the following:	
IS Awarding omponent	Compone          1       Proj         2       PD/         3       Nan	nt must of ect numl PI or Com ne of the	contain, at a n per ntact PD/PI Investigator DOCUMI	ninimum, If multip Name of	the following:  ble used f the Investigator with DOCUMENT	the financial
IS Awarding omponent	Compone          1       Proj         2       PD/         3       Nan         ENT NUMBE       00-001A	nt must of ect numl PI or Com ne of the R	contain, at a n per ntact PD/PI Investigator DOCUMI REVISIO	ninimum, If multip Name of ENT DN #	the following: ple used f the Investigator with DOCUMENT REVISION DATE	the financial EFFECTIVE DATE

©2013, Fresenius Medical Care Holdings, Inc. All Rights Reserved.



		conflict of interest
4	Name of the entity	Name of the entity with which the Investigator has a financial conflict of interest.
5	Nature of the financial interest.	i.e. equity, consulting fee, honorarium, trave reimbursement.
6	Value of the financial interest.	<ul> <li>Note that dollar ranges are permissible</li> <li>such as \$5000-\$9,999; \$10-19,999;</li> <li>amounts between \$20,000-\$100,000 by increments of \$20,000;</li> <li>amounts above \$100,000 by increments of \$50,000) or</li> <li>a statement that the interest is one whose value cannot be readily determined through reference to public prices or fair market value.</li> </ul>
7	Description of how the financial interest relates to the PHS-funded research and;	The basis for FMCNA's determination that the financial interest conflicts with such research
8	Brief description of the key elements of FMCNA's management plan.	<ul> <li>Includes;</li> <li>o Role and principal duties of the conflicted Investigator in the research project;</li> <li>o Conditions of the management plan;</li> <li>o How the management plan is designed to safeguard objectivity in the research project;</li> <li>o Confirmation of the Investigator's</li> </ul>

DOCUMENT NUMBER	DOCUMENT REVISION #	DOCUMENT REVISION DATE	EFFECTIVE DATE
COR-CR-G-000-001A			11/27/2013
Title: Financial Conflict of Interest f Research	Page 11 of 14		
©2013, Fresenius Me	edical Care Holdings, I	nc. All Rights Reserve	d.



		agreement to the management plan;				
		o How the management plan will be				
		monitored to ensure Investigator				
		compliance; and				
		o Other information as needed.				
Retrospective Review for	<u>Im</u>	portant: Retrospective review must be completed within 120 days.				
Non- compliance; Non-disclosure		e Designated Official will conduct a retrospective review and report to the licable COIC if:				
of FCOI	•	A financial conflict of interest is not identified or managed or not handled in a timely manner, or				
	•	Investigator does not disclose significant financial interest; or				
	٠	Investigator fails to comply with the management plan.				
Documentation of Retrospective Review		e FMCNA Designated Official will document the retrospective review and lude at a minimum the following key elements:				
	1	Project number				
	2	Project title				
	3 PD/PI or Contact PD/PI if multiple used					
	4 Name of the entity with which the Investigator with the FCOI.					
	5	Name of the entity with which the Investigator has a financial conflict of				
		interest				
	6	Reason(s) for the retrospective review;				
	1					
	7	Detailed methodology used for the retrospective review;				

- 8 Findings of the review; and
- 9 Conclusions of the review.

**Retrospective** Based upon the results of the retrospective review, the COIC will:

DOCUMENT NUMBER	DOCUMENT REVISION #	DOCUMENT REVISION DATE	EFFECTIVE DATE	
COR-CR-G-000-001A			11/27/2013	
Title: Financial Conflict of Interest f Research	Page 12 of 14			
©2013, Fresenius Medical Care Holdings, Inc. All Rights Reserved.				



Review – Corrective Actions	<ul> <li>If bias is found, promptly notify the PHS Awarding Component and submit a mitigation report to the PHS Awarding Component including : <ul> <li>The key elements documented in the retrospective review</li> <li>Description of the bias on the research project and FMCNA's plan of action to eliminate or mitigate the effect of the bias.</li> </ul> </li> <li>Recommend a corrective action plan for the Investigator including up to terminating future and current research privileges.</li> <li>Continue to submit annual FCOI reports to the PHS Awarding Component outlining the status of the corrective action.</li> </ul>				nt including : ew CNA's plan of ncluding up to
PHS-funded Research and Sub-recipients	• Sub graniees/Sub-recipients				
	If			Then	
	Sub-recipient's Investigator must comply with the Sub- recipient's FCOI policy,Sub-recipient shall:• certify as part of the agreement that its policy is compliant with 42 CFR Part 50 Subpart F (Grants and cooperative agreements), and 45 CFR Part 94 (contracts).Note: The sub-recipient's agreement must specify time periods for the sub-recipient to report all identified FCOI to the FMCNA Entity.				
	Sub-recipient's	4	-	nt shall specify time pe	
	Investigator mus			ent to submit all Inves	
DOCUME	ENT NUMBER		DCUMENT EVISION #	DOCUMENT REVISION DATE	EFFECTIVE DATE
COR-CR-G-00	00-001A				11/27/2013
Research	Title: Financial Conflict of Interest for Public Health Service (PHS) Funded       Page 13 of 14         ©2013, Fresenius Medical Care Holdings, Inc. All Rights Reserved.				



DOCUM	ENT NUMBER	DOCUMENT REVISION #	DOCUMENT REVISION DATE	EFFECTIVE DATE	
Related Documents	FMCNA Clinical	Research Potential Cor	nflict of Interest Disclo	osure Form	
	<ul> <li>PHS funded or contracted studies records:</li> <li>HHS may inquire at any time (before, during, or after award) into any Investigator disclosure of financial interests.</li> <li>HHS may inquire regarding FMCNA's review (including retrospective review) and response to a disclosure, regardless of whether the disclosure resulted in FMCNA's determination of a FCOI, including a requirement to submit, or permit on site review of, all records pertinent to compliance with the regulation.</li> </ul>				
Document Retention	• must be reta	es, their review, detern ained for at least 3 year litures report.	•	-	
Reporting an Identified FCOI to HHS	<ul> <li>will include specific values include specific values include specific values includes with the submitted to the submitted to the submitted to the specific values values</li></ul>	s and cooperative agreenee NIH through the eR. NOT-OD-09-072; <u>http</u> <u>0-09-072.html</u> ] acts, reports should be	ements, all FCOI report A Commons FCOI Mo p://grants.nih.gov/grant	rts must be odule. [NIH ts/quide/notice-	
	of all sub-recipien	OI reports to the PHS t Investigators prior to uently identified FCOI	the expenditure of fun		
	comply with the FMCNA policy	disclosures of Official.	f SFI to the FMCNA D	Designated	

DOCUMENT NUMBER	<b>REVISION</b> #	<b>REVISION DATE</b>	DATE	
COR-CR-G-000-001A			11/27/2013	
Title: Financial Conflict of Interest f Research	Page 14 of 14			
©2013, Fresenius Medical Care Holdings, Inc. All Rights Reserved.				